Alvotech and Fuji Pharma are entering into an exclusive partnership for the commercialization by Fuji Pharma of Alvotech’s biosimilar portfolio in Japan.
 
Alvotech will be responsible for development and supply of multiple high value biosimilar assets from its current product pipeline, while Fuji Pharma will be responsible for registration and commercialization of these assets in Japan. Alvotech’s biosimilar portfolio includes high value products used in advanced therapies of oncology, ophthalmology and autoimmune disease that generated over $32 billion in global sales in 2017, according to Evaluate data.
 
The partnership has been made with a view to establishing a long-term relationship that also gives Fuji Pharma the opportunity to invest in Alvotech’s capital structure. In partnering with Fuji Pharma, Alvotech will gain access to Japan’s fast-growing biosimilars market, forecasted to grow as much as 35% CAGR over the next years. 
 
“We are very proud to announce our strategic alliance with Fuji Pharma, a pioneer in the Japanese biosimilars market,” said Rasmus Rojkjaer, chief executive officer, Alvotech. “We strongly believe that in combining Alvotech’s significant manufacturing capacity and high value biosimilars portfolio with Fuji Pharma’s deep market experience, we will together be staking a place as leaders in Japan’s rapidly growing biosimilars market. We are excited to continue delivering on our expanding commitment to bring high quality biosimilars to patients worldwide.”
 
Eiji Takamasa, president and chief executive officer, Fuji Pharma, said, “Both Fuji Pharma and Alvotech share the same management philosophy that fuels our excitement to partner with each other. Together we will ensure that patients in Japan will get high quality biosimilars, while reducing the cost burden on the aging Japanese society.  Fuji Pharma’s strong market reach in Japan, complemented with Alvotech’s futuristic portfolio of the expected first-to-launch biosimilar products, will provide the critical synergies for the success of this partnership.”